Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

09/06/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.17%, closing at 50872.11 points; the Nasdaq Composite dropped by 0.97%, closing at 25678.82 points; the S&P 500 Index dropped by 0.26%, closing at 7386.65 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Nuvalent, Inc. Class A: Overnight gain 39.3%, Surges on GSK Cash Acquisition Announcement Amid Premium Valuation

Nuvalent, Inc., incorporated in Delaware in January 2017, is a clinical-stage biopharmaceutical company focused on developing precision targeted therapies for cancer patients. Leveraging the team's expertise in chemistry and structure-based drug design, the company is dedicated to developing innovative small molecule therapeutics designed to overcome the limitations of existing treatments targeting validated kinase targets. Current kinase inhibitors face several key limitations: kinase resistance, where new mutations in kinase targets lead to resistance against existing therapies; insufficient kinase selectivity, as current treatments may inhibit structurally similar kinase targets and cause off-target adverse effects; and limited brain penetration, which impacts the treatment efficacy for diseases that have spread or metastasized to the brain.

**GSK Announces $10.6 Billion Cash Acquisition of Nuvalent, Inc. Class A (NUVL)** Nuvalent, Inc. Class A (NUVL) shares surged 39.3% following GlaxoSmithKline's announcement of a $10.6 billion all-cash acquisition. The deal values NUVL at $124 per share, representing a 40% premium to the previous trading day's closing price of $88.49. This transaction marks GSK's largest acquisition in over a decade, securing three critical lung cancer therapeutic assets, including lead candidates zidesamtinib and neladalkib. Neladalkib has demonstrated exceptional clinical performance, achieving a 31% response rate in previously treated ALK-positive non-small cell lung cancer patients and an impressive 86% response rate in treatment-naïve patients. GSK projects the acquisition will contribute to revenue growth beginning in 2027 and enhance earnings per share from 2029 onwards. The premium valuation reflects strong market confidence in the precision-targeted cancer therapy specialist's innovative pipeline and commercial potential.

Alignment Healthcare, Inc.: Overnight gain 25.1%, Surges Amid Healthcare Sector Strength and Strong Revenue Growth

**Alignment Healthcare, Inc. Profile** Alignment Healthcare, Inc., incorporated in Delaware in 2013, is a healthcare company dedicated to improving health outcomes for the senior population. The company operates as a next-generation consumer-centric platform focused on transforming the healthcare experience for older adults. The company primarily serves senior customers nationwide through its Medicare Advantage plans, delivering customized healthcare solutions tailored to meet the specific needs of elderly populations across different regions. Alignment Healthcare's platform employs a consumer-focused service model designed to enhance the quality of healthcare delivery for seniors. As a specialized Medicare Advantage provider, the company positions itself at the intersection of healthcare innovation and senior care, leveraging its consumer-oriented approach to address the evolving healthcare needs of America's aging demographic.

Notably, Alignment Healthcare, Inc. (ALHC) stock surge was driven by multiple positive catalysts. The healthcare sector experienced broad-based strength, with UnitedHealth Group receiving rating upgrades and target price increases from Bank of America Securities and Morgan Stanley, lifting sector peers collectively. The company demonstrated strong fundamentals, with fiscal 2025 total revenue reaching $3.95 billion, representing a substantial 46.1% year-over-year increase. Membership expanded to 284,800 members, reflecting robust business momentum. Additionally, Alignment Healthcare, Inc. (ALHC) advanced significantly in the Fortune 1000 rankings, climbing from 987th to 791st position, and was recognized among the World's Most Admired Companies as the only Medicare Advantage-focused enterprise selected, substantially enhancing its market positioning. Over 100% of members enrolled in 4-star or higher rated plans, demonstrating superior service quality advantages. These multiple positive factors collectively propelled the stock price surge of 25.1%.

Payoneer Global Inc.: Overnight gain 24.3%, Surges Amid Strong Fintech Performance and Cross-Border Payment Growth

Payoneer Global Inc. is a Delaware-incorporated financial technology company established in 2005. The company operates a global payments and commerce platform that delivers cross-border payment solutions to millions of digital businesses through its integrated technology infrastructure comprising APIs, web interfaces, mobile applications, and machine learning capabilities. The company's core business model centers on providing clients with comprehensive single-point access services, integrating both localized and international payment channels through a unified platform to facilitate global money transfer and collection capabilities, thereby effectively supporting clients' business expansion requirements.

**Payoneer Global Inc. (PAYO) Surges on Multiple Growth Catalysts** Payoneer Global Inc. (PAYO) stock's recent surge reflects a confluence of positive factors driving investor sentiment. As a leading global digital payments platform, the company benefits from sustained growth in cross-border e-commerce and digital business transformation, with its comprehensive global payment solutions gaining strategic market positioning. The company's machine learning-powered payment infrastructure delivers competitive advantages in risk management and user experience, strengthening its market position. The substantial 24.3% rally appears linked to better-than-expected financial performance, strategic partnership developments, or new business expansion initiatives. Additionally, the broader fintech sector's valuation recovery has provided supportive momentum for PAYO shares. With year-to-date gains of 13.7%, market participants demonstrate confidence in Payoneer's long-term value proposition within the global digital payments ecosystem, reflecting optimism about the company's growth trajectory and market opportunities ahead.

Velo3D: Overnight gain 19.7%, Surges on Strategic Partnership with Aurelia Technologies for Gas Turbine Manufacturing

**Velo3D Incorporated: Pioneering Metal 3D Printing Technology Solutions** Velo3D, Inc., incorporated on September 11, 2020, and domiciled in Delaware, is a leading technology company specializing in advanced metal 3D printing solutions. The company delivers comprehensive end-to-end manufacturing capabilities through its integrated approach combining proprietary software, hardware, and process control innovations, enabling superior quality control for high-volume production and enhanced component performance. The company's core product portfolio encompasses the VELO3D print preparation software, Sapphire laser powder bed additive manufacturing systems, and quality assurance software solutions. These integrated technology platforms enable manufacturers to accelerate product development cycles, enhance market responsiveness, and achieve operational cost optimization. As an industry pioneer, Velo3D has introduced breakthrough SupportFree metal 3D printing technology, which transcends conventional manufacturing constraints and enables precision fabrication of complex geometric structures previously deemed unmanufacturable through traditional methods. Headquartered in Silicon Valley, Velo3D has garnered industry recognition for its technological innovation capabilities, receiving nomination as one of Fast Company's Most Innovative Companies globally in 2021, underscoring the company's position at the forefront of additive manufacturing technology advancement.

Velo3D (VELO) shares surged 19.7% following the company's announcement of a strategic partnership with Aurelia Technologies. The collaboration aims to advance additive manufacturing technology applications in next-generation gas turbine systems. The partnership encompasses a phased project approach, including component feasibility assessments, materials process development, and qualification certification utilizing Velo3D's Sapphire XC platform for small-scale production. The initiative focuses on evaluating additive manufacturing advantages for specific turbine components and high-performance alloys, targeting enhanced performance, reduced delivery cycles, and improved manufacturability. Gas turbine systems represent a high-barrier industrial sector, positioning this partnership as a gateway for Velo3D (VELO) into high-value markets. The collaboration validates the company's 3D metal printing technology competitiveness in premium manufacturing applications. Market sentiment has turned increasingly optimistic regarding the company's growth prospects in aerospace and energy sectors, driving the significant single-day stock appreciation.

NetClass Technology Inc Class A: Overnight gain 18.6%, Surges Amid Blockchain Education Innovation and Strategic Partnership Growth

NetClass Technology Inc. (Class A) was incorporated in May 2003 as an educational technology service provider established by Longsoft Group in collaboration with domestic and international professionals. The company's core business operations encompass educational digitalization products and services, software development, smart classroom solutions, mobile learning platforms, as well as cloud computing, big data, and blockchain technology services. Since 2016, the company has strategically pivoted its technology development focus toward the application of mobile internet, cloud computing, and big data technologies within the education sector. In 2018, NetClass Technology pioneered the launch of the EDC Education Chain project, marking the first practical application of blockchain technology in China's domestic education industry. The company has established a strategic partnership with the Shanghai Municipal Education Commission's Credit Bank Platform. The company's proprietary platform products, including the Credit Wallet and Learning Voucher systems, represent innovative applications of blockchain technology in the educational technology sector. NetClass Technology has obtained recognition as a Shanghai High-Tech Enterprise, achieved "Double Software" qualification certification, and serves as a core member organization of the Shanghai Modern Service Industry Association.

NetClass Technology Inc Class A (NTCL) stock gains reflect multiple contributing factors. The company demonstrates significant technological advantages in blockchain education applications, notably through its EDC Education Chain launched in 2018—China's first blockchain implementation in the education sector—showcasing strong innovation capabilities. The accelerating digital education transformation has driven sustained demand growth for smart education solutions, creating substantial business development opportunities. NTCL's strategic partnership with Shanghai Municipal Education Commission's Credit Bank Platform provides crucial policy support for educational sector expansion. The company's innovative products, including Credit Wallet and Learning Vouchers, have gained industry recognition, bolstering market confidence in its growth prospects. As a Shanghai-certified high-tech enterprise, NTCL's professional positioning and technical expertise in educational technology receive market validation, providing fundamental support for the stock appreciation. The convergence of technological leadership, market demand expansion, and strategic partnerships positions the company favorably in the evolving education technology landscape.

CECO Environmental Corp.: Overnight gain 18.5%, Surges Amid Major Acquisition Completion and Raised Guidance

**CECO Environmental Corp. Profile** CECO Environmental Corp., originally incorporated in 1966 and reincorporated in Delaware in 2002, operates as an environmentally-focused diversified industrial enterprise. The company specializes in serving global industrial air quality, industrial water, and energy transition markets through innovative technology and specialized application solutions. The corporation enables business growth through safe, clean, and efficient solutions while protecting personnel, environmental assets, and industrial equipment. CECO's technology portfolio delivers enhanced air and water quality improvements, optimized emissions management, and increased energy efficiency across multiple sectors. The company's advanced engineering applications serve high-value end markets including power generation, hydrocarbon processing and transportation, electric vehicle manufacturing, polysilicon production, semiconductor and electronics, battery manufacturing and recycling, specialty metals and steel production, beverage and packaging, water treatment, and other specialized industrial terminal markets. CECO Environmental's comprehensive solutions platform positions the company to capitalize on growing demand for environmental compliance and sustainability technologies across diverse industrial applications.

CECO Environmental Corp. (CECO) shares surged following the convergence of multiple positive catalysts. The company successfully completed its major acquisition of Thermon Group, which is expected to generate over $40 million in cost synergies, with integration proceeding smoothly and benefits already materializing. CECO significantly raised its 2026 guidance, projecting revenues of $1.275-1.375 billion, representing approximately 20% year-over-year growth. Adjusted EBITDA is forecast to increase 25% to $195-225 million. Additionally, the company's traditional business achieved record order volumes in early June, capturing robust market opportunities in high-growth sectors including power generation, data centers, and semiconductors. The company expects full-year free cash flow to reach over 55% of adjusted EBITDA, demonstrating exceptional cash generation capabilities. These positive developments have substantially boosted investor confidence, driving the stock's upward momentum as the market recognizes CECO's enhanced growth prospects and operational efficiency improvements.

Oil-Dri Corporation of America: Overnight gain 17.4%, Surges Amid Strong Q3 Earnings and Record Dividend Increase

Oil-Dri Corporation of America is a Delaware-incorporated entity that succeeded an Illinois corporation established in 1946. The company operates as a specialty sorbent products manufacturer, focusing on the development, mining, production, and distribution of clay mineral-based solutions, including calcium bentonite, attapulgite, and diatomaceous earth shale compositions. The corporation's diversified product portfolio encompasses agricultural and horticultural chemical carriers, animal health and nutrition products, cat litter merchandise, bleaching earth for fluid purification and filtration applications, industrial and automotive floor absorbents, and sports field maintenance products. With an extensive operational history in the sorbents industry, Oil-Dri Corporation maintains a broad market presence across multiple end-market segments, including agricultural, industrial, and consumer product applications. The company's clay mineral-based technologies serve diverse customer needs spanning from agricultural chemical delivery systems to consumer household products and industrial processing solutions.

Oil-Dri Corporation of America (ODC) shares surged driven by multiple positive catalysts converging simultaneously. The company delivered impressive third-quarter results with earnings per share reaching $1.00, representing a substantial 25% year-over-year increase, while revenue climbed 9.37% to $126.3 million, providing solid fundamental support for the stock appreciation. Significantly, ODC announced its 23rd consecutive annual dividend increase, raising quarterly cash dividends from $0.2050 to $0.2250 per common share and from $0.153 to $0.168 per Class B share, reflecting approximately 10% growth for both share classes. This milestone dividend growth streak demonstrates the company's robust financial strength and long-term shareholder commitment. Additionally, the board authorized a new share repurchase program for up to 500,000 common shares, signaling management's strong confidence in future prospects. ODC's continuous cash dividend payments spanning over 50 years since 1974 further reinforces investor confidence in its sustained operational stability and reliability.

Aduro Clean Technologies (Uplisting): Overnight gain 17.2%

Aduro Clean Technologies Inc. was incorporated in British Columbia on January 10, 2018. Following the completion of its merger and acquisition transaction with Aduro Energy, the company has pivoted its core operations to focus on the clean technology business previously operated by Aduro Energy. Aduro Energy, an early-stage cleantech company headquartered in Ontario, specializes in developing innovative chemical conversion process technologies. The company has successfully developed advanced processing capabilities for converting waste plastics and low-grade renewable feedstocks into renewable fuels and specialty chemicals. The organization has established a highly adaptable chemical recycling technology platform that integrates three core proprietary technologies: Hydrochemolytic™ plastic upcycling technology, Hydrochemolytic™ bitumen upgrading technology, and Hydrochemolytic™ renewable feedstock upgrading technology. These technological solutions provide new commercialization pathways for waste-to-resource conversion, aligning with current market trends toward circular economy principles and sustainable development initiatives.

**Aduro Clean Technologies (Uplisting) (ADUR) Stock Surge Driven by Multi-Factor Catalyst** ADUR's recent stock price appreciation reflects a confluence of strategic and market factors. The company's core competencies in clean technology are increasingly prominent, with its proprietary Hydrochemolytic™ platforms for plastic upcycling, bitumen upgrading, and renewable feedstock processing effectively converting waste plastics into renewable fuels and specialty chemicals, aligning with global environmental policy trends. Accelerating carbon neutrality commitments worldwide are driving robust demand growth in waste plastic recycling and renewable energy markets, creating substantial commercialization opportunities for the company's technology platform. Post-integration with Aduro Energy, operational efficiency improvements and enhanced business focus have strengthened the company's market position. The chemical recycling platform's feedstock flexibility provides competitive advantages and enhanced market adaptability. As an innovative player in the cleantech sector, ADUR benefits from investor premiums attributed to environmental technology equities, sustaining upward momentum in share price performance.

Cartesian Therapeutics, Inc.: Overnight gain 16.9%, Surges Amid Strategic Partnership for Autoimmune CAR-T Cell Therapy Development

Cartesian Therapeutics, Inc. is a Delaware-incorporated clinical-stage biotechnology company focused on developing RNA cell therapies for autoimmune disorders. The company's lead product candidate, Descartes-08, represents a potentially first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) currently undergoing Phase 2b clinical trials for generalized myasthenia gravis. The company has plans to initiate Phase 2 studies targeting systemic lupus erythematosus and ocular and vascular autoimmune conditions. Cartesian operates a wholly-owned current Good Manufacturing Practice (cGMP)-compliant manufacturing facility in Gaithersburg, Maryland.

Cartesian Therapeutics, Inc. (RNAC) shares surged following the announcement of a strategic collaboration agreement with Westgene Biopharma. The partnership integrates core technology platforms from both companies, combining WestGene's targeted lipid nanoparticle technology with Cartesian's Descartes-08 mRNA payload technology to develop in-vivo CAR-T cell therapies for autoimmune diseases. The agreement includes undisclosed upfront and milestone payments, demonstrating confidence in the project's commercial prospects. Cartesian has outlined a clear clinical development timeline, planning to initiate clinical trials in myasthenia gravis patients in the second half of 2026, with clinical data expected in the first half of 2027. Additionally, the company will advance multiple proprietary next-generation anti-BCMA CAR constructs, further expanding its product pipeline. This collaboration represents technological innovation in autoimmune disease treatment, offering potential advantages of greater convenience and lower costs compared to traditional ex-vivo CAR-T therapies. Market sentiment remains optimistic regarding the development prospects.

Alto Neuroscience, Inc.: Overnight gain 16.0%, Surges Amid Positive Clinical Trial Feedback and Precision Medicine Market Recognition

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware on March 25, 2019. The company's core business operations focus on developing personalized therapeutic solutions for psychiatric disorders through the application of its proprietary precision psychiatry technology platform, which enables precise identification and utilization of brain biomarkers. The company's current pipeline encompasses multiple clinical-stage assets targeting key therapeutic areas including major depressive disorder, bipolar depression, schizophrenia, and Parkinson's disease, among other significant neuropsychiatric conditions.

Alto Neuroscience, Inc. (ANRO) shares surged 16.0% overnight, driven by multiple converging factors. The clinical-stage biopharmaceutical company, specializing in precision psychiatry, has gained significant market recognition for its core technology platform utilizing brain biomarker identification to develop personalized treatment protocols. The company's clinical trial progress in major depressive disorder, bipolar depression, and schizophrenia has received positive feedback, enhancing investor confidence. The precision medicine sector continues gaining momentum in capital markets, with ANRO's innovative treatment approach aligning with prevailing industry trends. Additionally, growing demand for mental health solutions, particularly heightened post-pandemic awareness of psychiatric disorder treatment, has bolstered market sentiment. The broader mental health market expansion provides substantial growth opportunities for specialized companies like ANRO. The stock's impressive 18.8% year-to-date performance reflects strong market optimism regarding the company's long-term prospects, providing fundamental support for the recent substantial price appreciation and reinforcing investor confidence in ANRO's strategic positioning within the precision psychiatry sector.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.